NDAORALSOLUTION
Approved
May 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
KHINDIVI (hydrocortisone) by PharmaIN is corticosteroid hormone receptor agonists [moa]. First approved in 2025.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KHINDIVI is an oral hydrocortisone solution approved by the FDA in May 2025, a corticosteroid hormone receptor agonist used to treat adrenal insufficiency and other corticosteroid-responsive conditions. It works by binding to glucocorticoid receptors to suppress inflammatory and immune responses. The oral solution formulation provides an alternative delivery method for patients requiring hydrocortisone therapy.
Growth16.7 years to LOE
Early-stage product in growth phase with potential for rapid commercial scaling as market awareness builds post-approval.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
Started Sep 2025
400 enrolled
Pancreas Head CancerPancreas AdenocarcinomaIPMN, Pancreatic+7 more
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
Started Jun 2025
26 enrolled
Hematopoietic and Lymphatic System Neoplasm
HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study
Started Oct 2022
180 enrolled
Healthcare-Associated PneumoniaVentilator Associated Pneumonia
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Started May 2022
55 enrolled
Congenital Adrenal Hyperplasia
Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction
Started Nov 2021
Worked on KHINDIVI at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.